Category: InVivo Therapeutics Corp.
Here's a look at some of the top Wall Street stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; InVivo's stock drops as ex-CEO dumps shares; Mevion Medical files for $69M IPO; ReWalk Robotics prices IPO at $36M, below range
InVivo Therapeutics ex-CEO Frank Reynolds has been liquidating his position in the company, putting even more weight on NVIV's already-pressured shares.
As if InVivo Therapeutics (OTC:NVIV) wasn't having a tough enough time already, the company's stock is under even more pressure as former CEO Frank Reynolds has been liquidating his position over the last few weeks.
Here's a look at some of the top legal news stories for medical device companies this week: Mirowski wants another bite at Supreme Court apple in Medtronic lawsuit; Shareholders sue InVivo Therapeutics, ex-CEO Reynolds over delayed FDA trial; Retractable Technologies urges appeals court to leave infringement win over BD alone; Boston Scientific can't sever Pinnacle pelvic mesh cases; Allergan can't delay shareholder vote on hostile Valeant bid
Shareholders sue InVivo Therapeutics and former CEO Frank Reynolds, alleging that the company concealed how long it would take to run a clinical trial under FDA guidelines.
Jorge Quinoy, president of Volcano Corp.'s U.S. & APLAC commercial sales, is leaving the company effective today.
Volcano (NSDQ:VOLC) said last week that its president for U.S. & APLAC commercial sales, Jorge (George) Quinoy, is leaving the company effective today.
Here's a look at some of the top funding stories for medical device companies this week: Intersect ENT registers $80M IPO for sinus implants; Mitralign raises another $8M; Device makers tally $67M in Pentagon deals; EndoShape raises $6.8M for vascular plugs and coils; EMBA Medical's still working on its $3M funding round
InVivo Therapeutics scales back its hydrogel delivery program, cutting nearly 1/3rd of its workforce to focus resources on its neuro-scaffold product line.